Meta-analysis of assay sensitivity and study features in clinical trials of pharmacologic treatments for osteoarthritis pain

Arthritis and Rheumatology

Volumn 66, Issue 12, 2014, Pages 3327-3336

  Dworkin, Robert H ^a   Turk, Dennis C ^b   Peirce Sandner, Sarah ^a   He, Hua ^a   McDermott, Michael P ^a   Hochberg, Marc C ^c   Jordan, Joanne M ^d   Katz, Nathaniel P ^e   Lin, Allison H ^f   Neogi, Tuhina ^g   Rappaport, Bob A ^f   Simon, Lee S ^h   Strand, Vibeke ⁱ  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e Analgesic Solutions   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h SDG LLC   (United States)

ⁱ NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); EFFECT SIZE; HAND OSTEOARTHRITIS; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; META ANALYSIS; OSTEOARTHRITIS; PAIN; PAIN INTENSITY; PATIENT IDENTIFICATION; PHARMACEUTICAL CARE; STUDY DESIGN; TREATMENT DURATION; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; REGRESSION ANALYSIS; TIME; TREATMENT OUTCOME;

HUMANS; OSTEOARTHRITIS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84912038881     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38869     Document Type: Article

References (44)

1. Bjordal JM, Klovning A, Ljunggren AE, Slordal L,. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007; 11: 125-38.
2. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18: 476-99.
3. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465-74.
4. European Medicines Agency. International Conference on Harmonisation Topic E10: Choice of control groups and related issues in clinical trials; 2001. URL: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm125912.pdf. Accessed August 27, 2012.
5. Katz N,. Methodological issues in clinical trials of opioids for chronic pain. Neurology 2005; 65: S32-49.
6. Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 2012; 153: 1148-58.
7. Rappaport BA, Cerny I, Sanhai WR,. ACTION on the prevention of chronic pain after surgery. Anesthesiology 2010; 112: 509-10.
8. Dworkin RH, Turk DC, Katz NP, Rowbotham MC, Peirce-Sandner S, Cerny I, et al. Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain 2011; 152 Suppl: S107-15.
9. Dworkin RH, Turk DC, Peirce-Sandner S, He H, McDermott MP, Farrar JT, et al. Assay sensitivity and study features in neuropathic pain trials: an ACTTION meta-analysis. Neurology 2013; 81: 1-9.
10. Dworkin RH, Peirce-Sandner S, Turk DC, McDermott MP, Gibofsky A, Simon LS, et al. Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database [published erratum appears in Osteoarthritis Cartilage 2011;19:919]. Osteoarthritis Cartilage 2011; 19: 483-92.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996; 17: 1-12.
12. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW,. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 1833-40.
13. Jensen MP, Karoly P,. Self-report scales and procedures for assessing pain in adults. In:, Turk DC, Melzack R, editors. Handbook of pain assessment. 3rd ed. New York (NY): Guilford Press; 2011. p. 19-44.
14. Higgins JP, Green S,. Cochrane handbook for systematic reviews of interventions. Chichester (UK): John Wiley & Sons; 2008.
15. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N,. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 2006; 59: 7-10.
16. Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146: 580-90.
17. Curtin F, Altman DG, Elbourne D,. Meta-analysis combining parallel and cross-over clinical trials. I: continuous outcomes. Stat Med 2002; 21: 2131-44.
18. Normand SL,. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999; 18: 321-59.
19. Whitehead A,. Meta-analysis of controlled clinical trials. Chichester (UK): John Wiley & Sons; 2002.
20. Hedges LV, Tipton E, Johnson MC,. Robust variance estimation in meta-regression with dependent effect size estimates. Res Syn Meth 2010; 1: 39-65.
21. Sterne JA, Egger M,. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-55.
22. National Collaborating Centre for Chronic Conditions. Osteoarthritis: national clinical guideline for care and management in adults. London: Royal College of Physicians; 2008.
23. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-62.
24. Wandell S, Juni P, Tendal B, Nuesch E, Villiger PM, Welton NJ, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341: c4675
25. Quessy SN, Rowbotham MC,. Placebo response in neuropathic pain trials. Pain 2008; 138: 479-83.
26. Gewandter JS, Dworkin RH, Turk DC, McDermott MP, Baron R, Gastonguay M, et al. Research design considerations for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain 2014; 155: 1683-95.
27. Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010; 341: c3515.
28. Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P,. Single-center trials show larger treatment effects than multicenter trials: evidence from meta-epidemiologic study. Ann Intern Med 2011; 155: 39-51.
29. Bafeta A, Dechartres A, Trinquart L, Yavchitz A, Boutron I, Ravaud P,. Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. BMJ 2012; 344: e813.
30. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013; 14: 365-76.
31. Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Transforming clinical research in the United States: challenges and opportunities. Workshop summary. Washington (DC): National Academies Press; 2010. URL: http://www.ncbi.nlm.nih.gov/books/NBK50892/pdf/TOC.pdf.
32. Doherty M, Dieppe P,. The "placebo" response in osteoarthritis and its implications for clinical practice. Osteoarthritis Cartilage 2009; 17: 1255-62.
33. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M,. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomized controlled trials. Ann Rheum Dis 2008; 67: 1716-23.
34. Hauser W, Bartram-Wunn E, Bartram C, Reinecke H, Tolle T,. Placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy: magnitude and patient-related factors. Pain 2011; 152: 1709-17.
35. Dworkin RH, Turk DC, Peirce-Sandner S, McDermott MP, Farrar JT, Hertz S, et al. Placebo and treatment group responses in postherpetic neuralgia versus painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain 2010; 150: 12-6.
36. Irizarry MC, Webb DJ, Ali Z, Chizh BA, Gold M, Kinrade FJ, et al. Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain 2009; 25: 469-76.
37. Greene K, Dworkin RH, Rowbotham MC,. A snapshot and scorecard for analgesic clinical trials for chronic pain: the RReACT database. Pain 2012; 153: 1794-7.
38. Trijau S, Avouac J, Escalas C, Gossec L, Dougados M,. Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010; 18: 1012-8.
39. Svensson O, Malmenas M, Fajutrao L, Roos EM, Lohmander LS,. Greater reduction of knee than hip pain in osteoarthritis treated with naproxen, as evaluated by WOMAC and SF-36. Ann Rheum Dis 2006; 65: 781-4.
40. Gentelle-Bonnassies S, Le Claire P, Mezieres M, Ayral X, Dougados M,. Comparison of the responsiveness of symptomatic outcome measures in knee osteoarthritis. Arthritis Care Res 2000; 13: 280-5.
41. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI,. Individual patient-versus group-level data meta-regressions for the investigation of treatment effect modifiers; ecological bias rears its ugly head. Stat Med 2002; 21: 371-87.
42. Scott-Lennox JA, McLaughlin-Miley C, Lennox RD, Bohlig AM, Cutler BL, Yan C, et al. Stratification of flare intensity identifies placebo responders in a treatment efficacy trial of patients with osteoarthritis. Arthritis Rheum 2001; 44: 1599-607.
43. Harris RE, Williams DA, McLean SA, Sen A, Hufford M, Gendreau RM, et al. Characterization and consequences of pain variability in individuals with fibromyalgia. Arthritis Rheum 2005; 52: 3670-4.
44. Farrar JT, Troxel AB, Haynes K, Gilron I, Kerns RD, Katz NP, et al. The effect of variability in the 7 day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study. Pain 2014; 155: 1622-31.